Publicador de contenidos

Investigación, Salud Materna, Infantil y Reproductiva


PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa

Foto: Geraint Hill / Stitching Pictures
01/03/2024 - 01/03/2027
Azucena Bardají
Co-funded by the European Union (EDCTP3)

Two vaccines designed for pregnant women to protect their unborn infant are entering late-phase development and will prevent infections from group B Streptococcus and respiratory syncytial virus, respectively. For these vaccines to be approved, they must work effectively without causing any unwanted responses. To implement these vaccines in countries with low resources, healthcare systems must be strengthened by improving vaccine safety monitoring and surveillance of infection and advancing vaccine delivery, vaccine confidence, and patient participation. The rapid rollout of electronic health records (EHR) in Kenya, Mozambique, Malawi, and Uganda offers an opportunity to use routine data to strengthen reporting of rates of adverse pregnancy, neonatal and infant outcomes, and any adverse events following immunisation; this will be imperative in informing and preparing for future large scale vaccination rollout campaigns.

Our approach will address key gaps in EHR to develop pregnancy registries embedded within national reporting systems to establish this data, including baseline rates of pregnancy and infancy outcomes for Tetanus and COVID-19 vaccines currently in use. These reporting systems will allow monitoring of potential safety signals once new vaccines are introduced. Experts in EHR, obstetrics and gynaecology, paediatrics, microbiology, clinical trials, and implementation research will develop the motivation and tools needed to monitor and evaluate current and future maternal vaccines.

We will work closely with the WHO, African Medicines Agency and country stakeholders, co-developing pregnancy registries, sentinel site microbiological surveillance systems, and maternal vaccination communications toolkits in preparation for the decade of maternal vaccines. Our programme of work culminates in a network of maternal vaccine trial sites that can rapidly evaluate vaccines in pregnancy from late-stage trials through to introduction on a national level.


Total Funding

4,322,509 €

Nuestro equipo


ISGlobal Team

Otros proyectos

Ver proyectos pasados


Validación continuada de la autopsia mínimamente invasiva (MIA) para la investigación de la causa de muerte en niños pequeños, y desarrollo de un centro de investigación y formación sobre el estudio de la causa de muerte


Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women


Improving Care through Azithromycin Research for Infants in Africa


Identification of Prematurity and Pre-Eclampsia as Causes of Mortality


MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention


Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations


Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone


Respiratory syncytial virus (RSV) in African pregnant women and children


Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance

HIV drug resistance (HIVDR)

Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique